Value of Preoperative Inflammatory Burden Index in Predicting Overall Survival and Progression in Nonmetastatic Muscle-Invasive Bladder Cancer

IBI and associated hematological markers are valuable for predicting survival outcomes in patients with MIBC. The findings support the integration of these biomarkers with other prognostic tools to enhance the accuracy of treatment outcome predictions.